RIGI and breast carcinoma: Interestingly the HDAC inhibitor Entinostat confers an additive benefit in driving cell death in combination with RIG-I activation (Figure 4C) in a mouse mammary carcinoma cell line that is typically insensitive to RIG-I induced cell death.